Abstract
Results HLA-B*5703-restricted CTL responses select for escape mutations in three Gag p24 epitopes, in a predictable order, and we show here that the accumulation of these mutations sequentially reduces viral replicative capacity in vitro. Despite this, in vivo data demonstrate that ultimately there is an increase in viral load concomitant with evasion of all three HLA-B*5703-restricted CTL responses. In HLA-B*5703-mismatched recipients, the previously described early benefit of transmitted HLA-B*5703-associated escape mutations is abrogated by the increase in viral load coincident with reversion. Conclusion These data demonstrate that, while costly escape from CTL responses can progressively attenuate the virus, high viral loads develop in the absence of adequate, continued CTL responses. These data underline the need for a CTL vaccine against multiple conserved epitopes. from AIDS Vaccine 2009 Paris, France. 19–22 October 2009
Highlights
Open AccessEvolution of HLA-B*5703 HIV-1 escape mutations and their impact on HIV-1 replicative capacity
HLA-B*57 is the class I allele most consistently associated with control of HIV replication, which may be linked to the specific HIV peptides that this allele presents to cytotoxic T lymphocytes (CTL), and the resulting efficacy of these cellular immune responses
These data demonstrate that, while costly escape from CTL responses can progressively attenuate the virus, high viral loads develop in the absence of adequate, continued CTL responses
Summary
Evolution of HLA-B*5703 HIV-1 escape mutations and their impact on HIV-1 replicative capacity. Address: 1University of Oxford, Oxford, UK, 2Yerkes Vaccine Center, Emory University, Atlanta, GA, USA and 3Zambia-Emory HIV Research Project, Lusaka, Zambia. Published: 22 October 2009 Retrovirology 2009, 6(Suppl 3):P130 doi:10.1186/1742-4690-6-S3-P130. AIDS Vaccine 2009 Anna Laura Ross Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have